Nabriva Therapeutics AG ADR (NASDAQ:NBRV)’s sales surged 1% in the recent quarter to 1.64M%, yielding EPS of $(0.55).
The firm generated $(14.33M) in net cash from operations in the previous quarter, bringing its balance at the close of the quarter to 27.07M%. Net change in cash balance from the preceding period was $(5.47M).
Let us look into the charts of the stock:
The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction. Longer term, the trend strength is Average.
With that, Nabriva Therapeutics AG ADR reported $78.66M in total assets at the close of the quarter. It recorded debt of -%, which was down/up falling from the previous period.
In the existing quarter, analysts are predicting EPS of $-5.61 from Nabriva Therapeutics AG ADR. That compares with EPS of $(0.55) in the last quarter.
Coming to earnings, the firm recorded EPS of $-2.47 in the last financial year, while EPS for the current year is anticipated to grow -7.80% over the prior year.
EPS metric is impacted by profits a firm generates in a certain period and the number of due shares in it has in that given period. For the previous quarter where EPS was EPS $(0.55), shares outstanding were 27.2M. In that quarter, Nabriva Therapeutics AG ADR incurred $- in cost of sales, resulting in gross profit of $- from the sales of 1.64M% it generated in the quarter.
Who owns Nabriva Therapeutics AG ADR? first, of the firm’s outstanding shares, 9.00M are free float. The firm?s shares sold short are 1.05%, implying a short ratio of 4.01.
As for the title, insiders own 9.60% of the firm, with that ownership moderately being a result of -5.95% insider transactions in the previous couple of months. Institutional shareholder ownership in the stock is 61.30%, stemming from 0.57% institutional transactions in the last few months.
Wall Street analysts on the average have a call of Buy on the stock of Nabriva Therapeutics AG ADR.
Nabriva Therapeutics plc (NASDAQ:NBRV) (“Nabriva Ireland”) today commenced the previously announced tender offer related to the exchange of American depositary shares (“Nabriva AG ADSs”) and common shares (“Nabriva AG Common Shares”) of Nabriva Therapeutics AG (“Nabriva AG”) for ordinary shares of Nabriva Ireland (the “Exchange Offer”). Once the Exchange Offer is completed, Nabriva AG will become a subsidiary of Nabriva Ireland, and it is expected that Nabriva Ireland will then become the publicly-traded parent company of the Nabriva Group and its subsidiaries with its tax residency in Ireland.